70
Participants
Start Date
May 19, 2014
Primary Completion Date
April 17, 2018
Study Completion Date
April 17, 2018
LEE011
LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
BYL719
BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
fulvestrant
Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
BKM120
BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
Novartis Investigative Site, Taipei
Novartis Investigative Site, Milan
Novartis Investigative Site, Madrid
Sarah Cannon Research Institute Onc Dept, Nashville
Novartis Investigative Site, Modena
Novartis Investigative Site, Lyon
Novartis Investigative Site, Singapore
University of Alabama at Birmingham/ Kirklin Clinic Dept Onc, Birmingham
Dana Farber Cancer Institute Onc. Dept., Boston
Novartis Investigative Site, Seoul
Novartis Investigative Site, Leicester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY